Biopharmaceutical innovator AbbVie is set to make a major splash at the American Academy of Dermatology Annual Meeting 2026, unveiling a sweeping wave of new data that could reshape how chronic skin diseases are treated.
At the high-profile gathering in Denver, the company will present 24 abstracts—including a late-breaking study—underscoring what it describes as “durable and sustained” treatment outcomes across a range of immune-mediated skin conditions.
“Through our data at AAD, AbbVie reinforces the importance of sustained efficacy and safety to re-shape standards of care and ultimately inform future treatment paradigms that can be transformative for people living with immune-mediated skin diseases,” said Andrew Anisfeld, vice president, global medical affairs, immunology, AbbVie.
“Our robust evidence across multiple clinical trials and real-world data sources for risankizumab and upadacitinib reaffirm AbbVie's dedication to supporting improved patient outcomes.”
Among the headline findings: long-term results from the KEEPsAKE-1 Phase 3 trial show 88% of psoriatic arthritis patients treated with risankizumab experienced no radiographic disease progression after nearly five years—an indicator of lasting disease control.
Meanwhile, a massive safety review of upadacitinib spanning more than 9,000 patient-years found consistent safety outcomes across age groups under 65, with no major cardiovascular events reported in younger patients aged 12 to 49.
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims. In patients with atopic dermatitis, nearly three-quarters of those achieving minimal disease activity reported little to no impact on quality of life—far outpacing those with less controlled disease.
Treatment benefits extended to hard-to-treat areas like the head and neck, where more than half of patients reached near-complete skin clearance within six months.
In psoriasis, new comparative data suggest patients receiving risankizumab achieved significantly higher skin clearance rates than those on deucravacitinib—along with markedly better symptom relief and quality-of-life scores.
The company is also zeroing in on conditions with outsized psychological impact, including genital and scalp psoriasis. New Phase 4 data show up to 100% of patients in some groups reported minimal quality-of-life disruption after 16 weeks of treatment.
In a related regulatory milestone, the U.S. Food and Drug Administration recently approved updated labeling for risankizumab, incorporating these findings into prescribing information.
Looking ahead, AbbVie is pushing into new territory. Late-breaking Phase 3 results will spotlight upadacitinib as a potential systemic treatment for vitiligo—marking the first time such data have reached this stage, though the therapy is not yet approved for the condition.
Separately, studies in alopecia areata showed significantly higher hair regrowth rates in patients taking upadacitinib compared with placebo, with no new safety concerns emerging.
Taken together, the data reinforce AbbVie’s aggressive bid to dominate the dermatology space, with a pipeline that spans chronic, visible, and often life-altering conditions.
